本研究旨在提供二十年来复发性急性淋巴细胞白血病 (ALL) 儿童的结果数据以及影响生存的变量。回顾性研究包括 2002 年 3 月至 2021 年 3 月期间在我们中心诊断和治疗并复发的儿童。总共包括 100 名儿童（64 名男孩，36 名女孩）； 80 人患有 B-ALL，20 人患有 T-ALL。 50 名儿童出现过早复发，25 名儿童出现早期和晚期复发。复发部位为骨髓 57 例，孤立中枢神经系统 (CNS) 10 例，孤立睾丸 1 例，骨髓和 CNS 联合复发 32 例。 36个家庭选择了最好的支持性护理；其中 23 人很早就复发了。在诱导化疗后病情缓解的 35 例患者中，32 例（91%）接受了造血干细胞移植（HSCT）； 17/32 (53%) 还活着并且没有疾病。总生存期 (OS) 为 19 岁 (19%)，中位随访时间为 23.5 个月，基于可测量疾病风险 (MRD) 的风险分层后生存期显着改善（4% vs 35%，P = 0.02）。极早期、早期和晚期复发的 OS 分别为 8%、28% 和 32% (P = 0.018)，骨髓、联合和孤立 CNS 复发的 OS 分别为 15%、12.5% 和 50% (P = 0.008) ). 复发性 ALL 仍然是一个挑战，接受 HSCT 的患者的 OS 分别为 19% 和 53%。复发后遗弃的现象仍然普遍存在，我们需要整合社会支持来提供护理和最佳治疗。

The present study aims to provide outcome data in children with relapsed acute lymphoblastic leukemia (ALL)over two decades and variables that impact survival.The retrospective study included children who were diagnosed and treated at our center and relapsed between March 2002 and March 2021.A total of 100 children (64 boys, 36 girls) were included; 80 had B-ALL, 20 had T-ALL. 50 children had a very early relapse, while 25 each had an early and late relapse. The site of relapse was bone marrow in 57, isolated central nervous system (CNS) in 10, isolated testicular in 1, and combined bone marrow and CNS relapse in 32 children. Thirty-six families opted for the best supportive care; 23 of these had very early relapse. Among the 35 who were in remission following induction chemotherapy, 32 (91%) underwent hematopoietic stem cell transplantation (HSCT); 17/32 (53%) were alive and disease-free. Overall survival (OS) was 19 (19%) with a median follow-up of 23.5 months with a significantly improved survival post-measurable risk of disease (MRD) based risk stratification (4% vs 35%, P = 0.02). The OS with very early, early, and late relapses were 8%, 28%, and 32% (P = 0.018), and 15%, 12.5%, and 50% with bone marrow, combined and isolated CNS relapses (P = 0.008).Relapsed ALL remains a challenge, with OS of 19% and 53% among those who underwent HSCT. Abandonment after relapse continues to be prevalent, and we need to integrate social support for providing care and optimal treatment.